Drawing for ENTEROME

USPTO serial 79126292

ENTEROME

Reviewed by CopyMark Law Group

Reg. 4561761Status 706Registered
Filing date
Status date
Registration date
Jul 8, 2014
Examiner
TANNER, MICHAEL R
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with ENTEROME?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Thomas M. Palisi

THOMAS M. PALISI Lerner David LLP20 Commerce DriveCranford, NJ 07016United States

Goods and services

ClassDescriptionStatusFirst use
001[ Chemical and biochemical substances used for the manufacture and preservation of foodstuffs, of pharmaceutical, cosmetic and veterinary products, namely, probiotic bacteria and probiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, prebiotic bacteria and prebiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, enzymes for use in the manufacture of food products and pharmaceutical preparations ]SECTION 71 - CANCELLED—
003[ Cosmetic products, namely, cosmetic creams ]SECTION 71 - CANCELLED—
005Pharmaceutical and medicinal products for human and veterinary use, namely, pharmaceutical preparations for treating metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; veterinary products, namely, anti-infective products for veterinary use, veterinary pharmaceutical preparations for treatment of metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases and diarrhea; medicinal products for human and veterinary use, namely, nutritional supplements containing probiotic compositions; sanitary products for use in medicine, namely, sanitary sterilizing preparations, disinfectants for sanitary purposes, sanitary preparations for medical use; dietetic food and substances for medical use in the nature of meal replacement products and prepackaged meal plans, namely, nutritional meal replacement bars adapted for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged entrees for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged snack foods for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged yogurts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged desserts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; nutritional supplements for medical use; food additives for medical use, namely, dietary fiber for treating metabolic disorders, gastroenterological disorders, diarrhea, constipation and irritable bowel syndrome; nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables, microorganisms and cropsACTIVE—
042Human pharmaceutical research; research services provided by a pharmaceutical laboratory, namely, providing medical research testing services in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; Providing medical and scientific research information in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; providing medical and scientific research information in the field of pharmaceutical and clinical trials; scientific laboratory services, genetic testing of laboratory animals for pharmaceutical research purposes; biological research in the fields of microbiology and chemistryACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 15, 2026INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Dec 22, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 22, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Apr 22, 202571AGREGISTERED-SEC.71 ACCEPTED—
Apr 21, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 9, 2024ES71TEAS SECTION 71 RECEIVED—
Jul 8, 2023REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jan 26, 2023RNWLINTERNATIONAL REGISTRATION RENEWED—
Dec 12, 2021INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Nov 4, 2021INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Nov 4, 2021INPCINVALIDATION PROCESSED—
Oct 10, 2021INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 10, 2021NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Feb 10, 2021C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Feb 10, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 29, 2020ES75TEAS SECTION 71 & 15 RECEIVED—
Jan 23, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 4, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 4, 2014FIMPFINAL DISPOSITION PROCESSED—
Oct 8, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 8, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 30, 2014ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Feb 12, 2014ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 14, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 11, 2014GPNXNOTIFICATION PROCESSED BY IB—
Dec 25, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 25, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 25, 2013NPUBNOTICE OF PUBLICATION—
Dec 6, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 2, 2013ALIEASSIGNED TO LIE—
Nov 7, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 22, 2013CNEAEXAMINERS AMENDMENT MAILED—
Oct 22, 2013XAECEXAMINER'S AMENDMENT ENTERED—
Oct 22, 2013CNEAEXAMINERS AMENDMENT -WRITTEN—
May 15, 2013RFNPREFUSAL PROCESSED BY IB—
Apr 22, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 22, 2013RFRRREFUSAL PROCESSED BY MPU—
Apr 20, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 19, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 17, 2013DOCKASSIGNED TO EXAMINER—
Mar 15, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 11, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 7, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance